The impact of flare on disease costs of patients with systemic lupus erythematosus

Arthritis Care and Research

Volumn 61, Issue 9, 2009, Pages 1159-1167

  Zhu, Tracy Y ^a   Tam, Lai Shan ^a   Lee, Vivian W Y ^b   Lee, Kenneth K C ^b   Li, Edmund K ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CLINICAL ASSESSMENT; CLINICAL FEATURE; CONTROLLED STUDY; COST OF ILLNESS; DEMOGRAPHY; DISEASE ACTIVITY; DISEASE DURATION; DISEASE EXACERBATION; DISEASE SEVERITY; EMPLOYMENT STATUS; EXPLANATORY VARIABLE; FEMALE; HEALTH CARE PLANNING; HUMAN; INCIDENCE; LINEAR REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MULTIPLE REGRESSION; QUESTIONNAIRE; RETROSPECTIVE STUDY; SELF CONCEPT; STATISTICAL SIGNIFICANCE; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADULT; COST OF ILLNESS; COST-BENEFIT ANALYSIS; DISEASE PROGRESSION; FEMALE; HEALTH CARE COSTS; HEALTH RESOURCES; HEALTH SURVEYS; HUMANS; LINEAR MODELS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX;

EID: 69749127429     PISSN: 21514658     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.24725     Document Type: Article

References (36)

1. Stoll T, Stucki G, Malik J, Pyke S, Isenberg DA. Further validation of the BILAG disease activity index in patients with systemic lupus erythematosus. Ann Rheum Dis 1996;55:756-760 (Pubitemid 26354438)
2. Buyon JP, Petri MA, Kim MY, Kalunian KC, Grossman J, Hahn BH, et al. The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: a randomized trial. Ann Intern Med 2005;142:953-962 (Pubitemid 40840309)
3. Petri M. Disease activity assessment in SLE: do we have the right instruments? Ann Rheum Dis 2007;66 Suppl 3:iii61- 4.
4. Petri M, Genovese M, Engle E, Hochberg M. Definition, incidence, and clinical description of flare in systemic lupus erythematosus: a prospective cohort study. Arthritis Rheum 1991;34:937-944
5. Gladman DD, Urowitz MB, Kagal A, Hallett D. Accurately describing changes in disease activity in systemic lupus erythematosus. J Rheumatol 2000;27:377-379 (Pubitemid 30095467)
6. Brunner HI, Feldman BM, Bombardier C, Silverman ED. Sensitivity of the Systemic Lupus Erythematosus Disease Activity Index, British Isles Lupus Assessment Group Index, and Systemic Lupus Activity Measure in the evaluation of clinical change in childhood-onset systemic lupus erythematosus. Arthritis Rheum 1999;42:1354-1360
7. Buyon JP, Tamerius J, Belmont HM, Abramson SB. Assessment of disease activity and impending flare in patients with systemic lupus erythematosus: comparison of the use of complement split products and conventional measurements of complement. Arthritis Rheum 1992;35:1028-1037
8. Ho A, Magder LS, Barr SG, Petri M. Decreases in anti-double-stranded DNA levels are associated with concurrent flares in patients with systemic lupus erythematosus. Arthritis Rheum 2001;44:2342-2349 (Pubitemid 32977502)
9. Edwards CJ, Lian TY, Badsha H, Teh CL, Arden N, Chng HH. Hospitalization of individuals with systemic lupus erythematosus: characteristics and predictors of outcome. Lupus 2003;12:672-676 (Pubitemid 37173663)
10. D'Cruz DP, Khamashta MA, Hughes GR. Systemic lupus erythematosus. Lancet 2007;369:587-596
11. Stoll T, Sutcliffe N, Mach J, Klaghofer R, Isenberg DA. Analysis of the relationship between disease activity and damage in patients with systemic lupus erythematosus: a 5-yr prospective study. Rheumatology (Oxford) 2004;43:1039-1044 (Pubitemid 39144453)
12. Moroni G, Quaglini S, Gallelli B, Banfi G, Messa P, Ponticelli C. The long-term outcome of 93 patients with proliferative lupus nephritis. Nephrol Dial Transplant 2007;22:2531-2539 (Pubitemid 47365517)
13. Ward MM, Pyun E, Studenski S. Mortality risks associated with specific clinical manifestations of systemic lupus erythematosus. Arch Intern Med 1996;156:1337-1344 (Pubitemid 26196894)
14. Hanly JG, McCurdy G, Fougere L, Douglas JA, Thompson K. Neuropsychiatric events in systemic lupus erythematosus: attribution and clinical significance. J Rheumatol 2004;31: 2156-2162 (Pubitemid 39453234)
15. Huscher D, Merkesdal S, Thiele K, Zeidler H, Schneider M, Zink A. Cost of illness in rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and systemic lupus erythematosus in Germany. Ann Rheum Dis 2006;65:1175-1183 (Pubitemid 44277392)
16. Lacaille D, Clarke AE, Bloch DA, Danoff D, Esdaile JM. The impact of disease activity, treatment and disease severity on short-term costs of systemic lupus erythematosus. J Rheumatol 1994;21:448-453 (Pubitemid 24102828)
17. Panopalis P, Yazdany J, Gillis JZ, Julian L, Trupin L, Hersh AO, et al. Health care costs and costs associated with changes in work productivity among persons with systemic lupus erythematosus. Arthritis Rheum 2008;59:1788-1795
18. Sutcliffe N, Clarke AE, Taylor R, Frost C, Isenberg DA. Total costs and predictors of costs in patients with systemic lupus erythematosus. Rheumatology (Oxford) 2001;40:37-47. (Pubitemid 32124046)
19. Hochberg MC, for the Diagnostic and Therapeutic Criteria Committee of the American College of Rheumatology. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter]. Arthritis Rheum 1997;40:1725.
20. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH, and the Committee on Prognosis Studies in SLE. Derivation of the SLEDAI: a disease activity index for lupus patients. Arthritis Rheum 1992;35:630-640
21. Gladman D, Ginzler E, Goldsmith C, Fortin P, Liang M, Urowitz M, et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum 1996;39:363-369 (Pubitemid 26085211)
22. Zhu TY, Tam LS, Lee VW, Hwang WW, Li TK, Lee KK, et al. Costs and quality of life of patients with ankylosing spondylitis in Hong Kong. Rheumatology (Oxford) 2008;47:1422-1425
23. Linnik MD, Hu JZ, Heilbrunn KR, Strand V, Hurley FL, Joh T, and the LJP 394 Investigator Consortium. Relationship between anti-double-stranded DNA antibodies and exacerbation of renal disease in patients with systemic lupus erythematosus. Arthritis Rheum 2005;52:1129-1137
24. Alarcon-Segovia D, Tumlin JA, Furie RA, McKay JD, Cardiel MH, Strand V, et al, and the LJP 394 Investigator Consortium. LJP 394 for the prevention of renal flare in patients with systemic lupus erythematosus: results from a randomized, double-blind, placebo-controlled study. Arthritis Rheum 2003;48:442-454
25. ACR Ad Hoc Committee on Neuropsychiatric Lupus Nomenclature. The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum 1999;42:599-608.
26. Leung GM, Bacon-Shone J. Hong Kong's health system: reflections, perspectives and visions. Hong Kong: Hong Kong University Press; 2006.
27. Grant C. The Hong Kong health care systems. Sydney: University of New South Wales; 1998.
28. Woo J, Lau E, Lau CS, Lee P, Zhang J, Kwok T, et al. Socioeconomic impact of osteoarthritis in Hong Kong: utilization of health and social services, and direct and indirect costs. Arthritis Rheum 2003;49:526-534 (Pubitemid 36988306)
29. Liljas B. How to calculate indirect costs in economic evaluations. Pharmacoeconomics 1998;13:1-7. (Pubitemid 128708606)
30. Weiss JE, Sison CP, Ilowite NT, Gottlieb BS, Eberhard BA. Flares in pediatric systemic lupus erythematosus. J Rheumatol 2007;34:1341-1344 (Pubitemid 46898119)
31. FitzGerald JD, Grossman JM. Validity and reliability of retro-spective assessment of disease activity and flare in observational cohorts of lupus patients. Lupus 1999;8:638-644
32. Ng KP, Manson JJ, Rahman A, Isenberg DA. Association of antinucleosome antibodies with disease flare in serologically active clinically quiescent patients with systemic lupus erythematosus. Arthritis Rheum 2006;55:900-904 (Pubitemid 44917463)
33. Nossent JC. Course and prognostic value of Systemic Lupus Erythematosus Disease Activity Index in black Caribbean patients. Semin Arthritis Rheum 1993;23:16-21.
34. Ibanez D, Urowitz MB, Gladman DD. Summarizing disease features over time. I. Adjusted mean SLEDAI derivation and application to an index of disease activity in lupus. J Rheumatol 2003;30:1977-1982
35. Hermosillo-Romo D, Brey RL. Diagnosis and management of patients with neuropsychiatric systemic lupus erythematosus (NPSLE). Best Pract Res Clin Rheumatol 2002;16:229-244 (Pubitemid 36526641)
36. Clarke AE, Penrod J, St Pierre Y, Petri MA, Manzi S, Isenberg DA, et al, and the Tri-Nation Study Group. Underestimating the value of women: assessing the indirect costs of women with systemic lupus erythematosus. J Rheumatol 2000;27: 2597-2604 (Pubitemid 30847933)